key: cord-0427318-lddx4rkr
authors: Dokainish, Hisham M.; Re, Suyong; Mori, Takaharu; Kobayashi, Chigusa; Jung, Jaewoon; Sugita, Yuji
title: The Inherent Flexibility of Receptor Binding Domains in SARS-CoV-2 Spike Protein
date: 2021-08-13
journal: bioRxiv
DOI: 10.1101/2021.08.06.455384
sha: 69de9c11956a786d99aac95241ec52cceea29252
doc_id: 427318
cord_uid: lddx4rkr

Spike (S) protein is the primary antigenic target for neutralization and vaccine development for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It decorates the virus surface and undergoes large conformational changes of its receptor binding domain (RBD) to enter the host cell, as the abundant structural studies suggest. Here, we observe Down, one-Up, one-Open, and two-Up-like structures in enhanced molecular dynamics simulations without pre-defined reaction coordinates. The RBDA transition from Down to one-Up is supported by transient salt-bridges between RBDA and RBDC and by the glycan at N343B. Reduced interactions between RBDA and RBDB induce the RBDB motions toward two-Up. Glycan shielding for neutralizing antibodies is the weakest in one-Open. Cryptic pockets are revealed at the RBD interfaces in intermediate structures between Down and one-Up. The inherent flexibility in S-protein is, thus, essential for the structure transition and shall be considered for antiviral drug rational design or vaccine development.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over a 190 million infections and 4 million deaths, as of July 2021 (https://coronavirus.jhu.edu/map.html). It represents an urgent need for an effective medical intervention strategy, to avoid further social and economic consequences 1 . Different types of vaccines, for example, those from Pfizer-BioNTech or Moderna using the mRNA of Spike (S) protein, are currently available, and there are several FDA approved drug candidates under consideration 2,3 . At the same time, more infectious mutants such as B.1.617.2 (Delta) and B.1.427 / B.1.429 (Epsilon) have appeared, and some evade from the immune system 4, 5, 6, 7 . Furthermore, the virus ability to infect a wide range of vertebrates, which could act as a reservoir, points out the future risk despite the vaccination progress 8 . A deeper understanding of the virus molecular structure and infection mechanism is crucial to stop the virus transmission including mutant strains 9 .

SARS-CoV-2, an enveloped positive single stranded RNA (+ssRNA) virus, has a large genome of approximately 30 kb encoding 29 proteins 9,10 . A transmembrane homotrimeric class I fusion glycoprotein decorating the virus, known as S-protein, plays a critical role in the viral cell entry 11, 12 . In an immediate response to the pandemic, over a hundred Cryo-electron microscopy (EM) and X-ray crystal structures of Sprotein have been reported and rapidly advanced in our understanding of the S-protein/receptor binding mechanism 13, 14, 15, 16, 17, 18, 19 . The N-terminal subunit (S1), which is composed of the N-terminal domain (NTD), the receptor binding domain (RBD) and two other subdomains (SD1 and SD2) ( Figure S1 ) 16, 20 , initially binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2) 19 . This binding is followed by priming of the C-terminal subunit (S2) and its large conformational change leading to the membrane fusion for the cell entry 12, 21 . S-protein is covered by 66 N-glycans, 22 per protomer, to evade from the host cell immune system 22, 23 . To block the initial binding with ACE2 either by stimulating the immune system using vaccines or by neutralized antibodies or small-molecule drugs is the primary target for medical interventions. Numerous Cryo-EM structures reveal that the RBDs can take inactive Down and active Up forms including one-Up, two-Up and three-Up conformations (Fig. 1a) 13, 14, 15, 16, 17, 21, 24, 25 . The RBDs are considered to undergo large conformational changes from the receptor inaccessible Down to the receptor accessible Up states in the ACE2 binding 16, 19, 26 . Note that most of the Cryo-EM structures representing the active Up forms were determined together with other proteins, such as antibodies or a fragment of ACE2 (Table S1) . A recent single molecule fluorescence resonance energy transfer (smFRET) experiment suggested that the Down-to-Up transition occurs in S-protein even without its ligand, taking at least one transient intermediate 27 Several microsecond-scale MD simulations showed conformational flexibility of the stalk in S-protein, different levels of glycan-shielding between Down and Up, and their relevance in the ACE2 binding 22, 28, 29 .

They also identified specific interactions between side-chain residues or those with glycans to stabilize either Down or Up 30, 31 . The timescale of the Down-to-Up transitions in S-protein is far slower than that attainable one in the current MD simulations, leaving the inherent flexibility and transition pathways largely unknown.

To overcome such difficulties, several enhanced sampling methods have been applied to investigate the Downto-1Up-transition, including targeted MD 31 , steering MD 32 , nudged elastic band/umbrella sampling 33 , adaptive sampling, 34 and weighted ensemble methods 35 . In most of these simulations, pre-defined reaction coordinates and/or bias potentials along the coordinates are used to enhance the motions of a single RBD in S-protein.

Here we apply the generalized replica exchange with solute tempering of selected surface charged residues (gREST_SSCR) 36 , which enhances domain motions of a protein by exchanging the solute temperature of selected surface residues. gREST_SSCR is distinct from the other simulations applied to S-protein in that no reaction coordinates as well as bias potentials are used, allowing us to examine the inherent flexibility of Sprotein involving more than one RBD. As listed in Table 1 , the RBD motion in the RBD/SD1 monomer, the trimeric S-protein in the presence and absence of glycans, is systematically investigated. The intrinsic flexibility of S-protein observed in the enhanced sampling MD simulations suggests new mechanisms underlying the Down-to-Up transitions, glycan shielding for the binding with antibodies, and unprecedented cryptic pockets in intermediate structures during the transitions. were selected as the solute region of gREST_SSCR ( Figure S3a ). 16 copies of each simulation system were used to cover the solute temperature range from 310 to 545 K. For this method to work, the solute temperatures between neighboring replicas must be exchanged frequently. This, indeed, happened in all three simulations,

showing sufficient overlaps of the potential energy distributions between neighboring replicas ( Figure S3 ). All 

As of December 2020, 126 Cryo-EM structures of S-protein, including all Down, one-Up, two-Up and three-Up conformations, were deposited in the Protein Data Bank (Table S1) 

To get insights into the contribution of each conformation to the ACE2 and neutralizing antibodies (nAbs) bindings, the accessibility of RBD is examined in terms of the Solvent Accessible Surface Area (SASA) 30 . Figures S9-S11) show the per-residue SASA around the receptor binding motif (residues I410 to V510, referred to as RBM hereafter) calculated for DSym, 1U, 1UO and 2UL conformations.

Four mutational residues of concern, K417, L452, E484, and N501 5 , are highlighted in red. In Down conformation (DSym), glycans at N165 and N343 largely shield RBM, leaving only small part accessible. RBM SASA increases in one-Up conformations (1U and 1UO) compared to Down, wherein 1UO exhibits the utmost increase suggesting its potential contribution to the receptor and/or antibody binding. In contrast, the SASA increases only slightly, even decreases locally around residue C480, in two-Up (2UL) conformation due to the mutual interactions between two RBDs. This finding suggests that one-Up conformations are the primary target of nAbs and the bindings of multiple nAbs likely proceed in a stepwise manner through one-Up conformations. Notably, K417 and N501 are accessible only in one-Up conformations as expected, while E484

is accessible in both Down and Up, inferring a widespread effect of E484 mutations. On the other hand, L452

is not accessible in any conformations and hence is expected to rarely affect the binding with either receptor or antibody, in wild type. 42 In contrast L452R mutation has shown to reduce neutralization 5 , suggesting its indirect contribution (e.g. the alternation of the S-protein conformational equilibria) to the immune escape. Figure 3c shows the calculated SASA for each epitope region of the four classes of nAbs (Class I: binds to Up for blocking ACE2, Class II: binds to Up and Down for blocking ACE2, Class III: binds outside RBM but recognize Up and Down, Class IV: binds Up without blocking ACE2) 5 . The epitope regions of Class I and II

antibodies are largely exposed and almost completely de-shieled from glycans in Up conformations. On the other hand, the epitope region for Class III antibody is less exposed and largely shielded by glycans. This agrees with that Class III antibodies recognize "glycoepitopes" 43 . Note that the epitope region of Class IV antibody is slightly exposed only in 1UO conformation. Further opening of RBD may allow the binding of Class IV antibody, such as CR3022, as suggested in a previous computational study 34 . Figure 3c shows the putative binding models with antibodies obtained by aligning the antibodies in Cryo-EM structures with each of Up conformations (see Figure S12 and S13 for detail). The 1U conformations can be targeted by any of Class I-III antibodies. On the other hand, 1UO and 2UL conformations are likely bound with Class I/II and Class II/III, respectively, suggesting the possible evade from some antibody attacks. We can also characterize the 1Up-to-2Up transition ( Figure S22a) , where RBDB undergoes the transitions. The increase in RBDB hinge angle is accompanied with a slight decrease in RBDA hinge angle. The latter decrease likely relates with the increases of the contacts and HBs between RBDA and RBDC from 1Ua, the top populated cluster in 1Up, to two-Up-like structures, for instance, K378A-E484C, Y369A-N487C and D427A-Y505C

( Figures S20 and S21 ). The numbers of contacts and HBs in two-Up-like structures are much less than those in one-Up, suggesting that a drastic reduction of inter-domain interactions is required toward a full two-Up conformations. No specific protein-glycan interactions are found to support the 1Up-to-2Up transition.

Finally, we examine the effect of glycans on the Down-to-Up transitions. Figure S22b shows the distributions of gREST_Down w/o glycan simulation on the HingeA-HingeB space. Without glycans on the surface of Sprotein, the structure distribution becomes wider, suggesting that S-protein is more flexible without glycans.

In addition, Down conformations are more diverse and asymmetric as one RBD has larger hinge angle distribution than the others. The transition mechanisms seem to be the same as those with glycans: RBDA and RBDC form transient interactions to support the Down-to-1Up transition. However, the two-Up-like structure (2UbL) is more connected with Down distribution, suggesting that structural integrity of S-protein is lost without glycans on the surface.

We applied a machine learning based algorithm (P2Rank) 45 to search for the formation of druggable pockets in the intermediates structures, I2a, I3a and I3b ( Figure S23a ). The same search was also carried out for Down and one-Up structures for comparison. Figure 5a shows the formation of two cryptic pockets (pocket1 and pocket2) at the interface of RBD in I2a, which are not observed in Down or one-Up. Figure 23c ). Table S5 shows a list of the index (ID) and binding energies of top ranked molecules. Notably for Nilotinib Nilotinib binds to either pocket1 or pocket2 in all first 9 binding modes with high binding affinity (Table S6) .

These results serve the two cryptic pockets as potential targets to stabilize intermediate structures and to prevent the formation of one-Up conformation responsible for the viral entry. 

In this study, we observed inherent flexibility of S-protein structures in absence of its ligand, exploring Down, (Figures 4 and S21) . The salt-bridge between R408A and D405C was also observed in the weighted ensemble simulations reported by Sztain et al. 35 This scenario is perturbed via protein-glycan interactions, in particular, those involving three glycans at N165B, N234B, and N343B as pointed out in previous studies 29, 30, 31 . In the current study, we highlighted the dual roles of these three glycans: the stabilization of one of the states and the driving force toward the other state. The glycans at N165 stabilize Down, representing a barrier for the Down-to-Up transition, while the glycan at N343B drives the transition. Finally, the glycan at N234B stabilizes one-Up-like conformation. This picture coincides with the experimental results by Henderson et al. 48 , where the population of one-Up drastically is reduced by the glycan deletions at N234 but increases by those at N165. As suggested previously 30 , the glycans at N165 may also stabilize one-Up conformation but as a minor role because it can adapt various orientations to that conformation ( Figure S25 ). The role of glycans at N343 is noteworthy in that it helps the position of RBD lift up from Down and supports it throughout the intermediates. This well explains the 20-fold reduction of the infectivity upon N343Q mutation observed by Li et al. 49 . Recently, a similar role of the glycans at N343 has been proposed by Sztain et al. 35

Since the drug repurposing studies 50 replication. In addition, Nilotinib as well as other top ranked molecules (Table S5) were also predicted to bind RBD in the previous virtual screening studies 52 The understanding of antibody responses is critical for vaccines and neutralizing antibody developments. The large exposure of RBDA in Up is shown in the current study, which is consistent with several previous studies 22, 30, 57 . We found that the accessibilities of RBM and the antibody epitopes, including mutational sites, depend sensitively on the RBD conformation, suggesting that each of the Up conformations (1U, 1UO and 2UL) tends to bind with distinct classes of antibodies. From our inspection, 1UO, which largely exposes RBM but the antibody epitopes of only Class I and II, is the potentially active conformation for both the ACE2 binding and evading from the antibody attack . Class I and II epitope regions include K417, E484, and N501, and their mutations could effectively enhance the infection either by enhancing the ACE2 binding (N501Y) 5 or reducing the antibody binding (K417N or E484K) 5 . Intriguingly, HB analysis shows that K417 and E484 respectively contribute to stabilize the intermediates I2a/I3b and 2UaL, likely enhancing the population of one-Up conformations. Note that L452 shows a little accessibility (Fig. 3) in contrast with the reported severe mutational effect to an antibody recognition 5 . The similar observation was also reported previously 42 . A possibility is that L452R mutation affects the structural flexibility of S-protein, which consequently gives rise to the enhanced infection. The last point to mention is that the predicted Up conformations are reasonably aligned with the antibody-bound S-protein Cryo-EM structures (Fig. S13) . Hence, the antibody bindings of Sprotein can be explained based on the conformer selection mechanism 58 . The exploration of conformational diversity of S-protein together with binding free-energy calculations followed by docking simulation would provide valuable structural insights with possible antibody bindings 59 .

The initial structures for S-protein head regions (residue 28-1135) were prepared based on the Cryo-EM 

We used Cryo-EM structures provided by "Spike protein and spike receptors" in Protein Data Bank (http://www.rcsb.org/covid19, deposited date 2020/02/04-2020/12/11, released by 12/30) in this study. Only structures where the number of residues is greater than 700 and the last residue >= 1122 for each protomer were selected in the analysis. 373 protomers of 126 structures and 121 trimeric structures from PDB were satisfied with the criteria and used in this study (Table S1 ). We adopt a method representing the structure with a 9-beads per protomer as used in the previous work of Henderson et al. 7, 39 Unlike their study, 27 beads consisting of three chains are used here. This coarse-grained model consists of 2 beads for RBD, 3 beads for NTD, 1 bead for SD1 and SD2 each, and 2 beads for the S2 region (CD and S2-b) (see Table S2 ). Principal 

The P2Rank software 45 

The trajectories are available from the corresponding authors upon reasonable request. Models and PDBs of representative structures in each cluster are available at https://covid.molssi.org/. The hinge angle is determined by three center of masses (COMs, yellow spheres) of the core and top residues of SD1 (green, Cα atoms only) and the core residues of RBD (red, Cα atoms only). The twist angle is determined by the aforementioned COMs with an extra COMs of the bottom residues of RBD. c) An overlay of two free energy landscapes at 310 K along the hinge angles in RBDA and RBDB obtained from gREST_Down (light blue) and gREST_Up (light cyan) simulations. d) Four representative conformations from MD simulations (cartoon representation) in comparison with Cryo-EM structures (light grey surface). Chain A, B, and C in S-protein are shown in red, blue, and green, respectively. Probability of finding the hydrogen bond (green) and contact (purple) pairs between protein residues or protein-glycans that markedly change along the transition pathway (DSym, I2a, I3a and 1UL). All hydrogen bond (probability of finding of >50%) and contact pairs (probability of finding of >70%) are shown in figure S19 and S20, respectively. b) Typical snapshots of the protein-protein and protein-glycan interactions along the transition pathway. Chain A, B, and C in the protein are shown in red, blue, and green surfaces, respectively. Glycans at N165, N234 and N343 are shown with spheres in lime, orange and yellow color, respectively. The transient N343B-RBDA contact are highlighted in red surface (top). The salt-bridges formed by R408A (blue), E406C (brown) and D405C (red) are also highlighted with black dashed circles (top and bottom), while the location of N234 glycan is highlighted with orange dashed circles. 

Characteristics of SARS-CoV-2 and COVID-19

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

SARS-CoV-2 variants, spike mutations and immune escape

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study

Coronavirus biology and replication: implications for SARS-CoV-2

The coding capacity of SARS-CoV-2

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Distinct conformational states of SARS-CoV-2 spike protein

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Site-specific glycan analysis of the SARS-CoV-2 spike

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Stabilizing the closed SARS-CoV-2 spike trimer

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein

Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states

Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket

SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome

A glycan gate controls opening of the SARS-CoV-2 spike protein

Exploring Large Domain Motions in Proteins Using Atomistic Molecular Dynamics with Enhanced Conformational Sampling

GENESIS 1.1: A hybrid-parallel molecular dynamics simulator with enhanced sampling algorithms on multiple computational platforms

New parallel computing algorithm of molecular dynamics for extremely huge scale biological systems

Controlling the SARS-CoV-2 spike glycoprotein conformation

Statistically optimal analysis of samples from multiple equilibrium states

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Determination of intermediate state structures in the opening pathway of SARS-CoV-2 spike using cryo-electron microscopy

P2Rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure

ZINC--a free database of commercially available compounds for virtual screening

The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro

Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein

Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach

Cold sensitivity of the SARS-CoV-2 spike ectodomain

Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation

Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein

Computational epitope map of SARS-CoV-2 spike protein

Induced fit, conformational selection and independent dynamic segments: an extended view of binding events

Unraveling the Coupling between Conformational Changes and Ligand Binding in Ribose Binding Protein Using Multiscale Molecular Dynamics and Free-Energy Calculations

Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane

Simulations Using the CHARMM36 Additive Force Field

Principal component analysis of native ensembles of biomolecular structures (PCA_NEST): insights into functional dynamics

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

This research used computational resources of the supercomputer Fugaku (The evaluation environment in the 

The authors declare no competing interests.

Supporting information is available for this paper.

The source code of GENESIS (https://www.r-ccs.riken.jp/labs/cbrt/) is distributed under the GNU Lesser General Public License version 3.